Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 4/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 5/20 | 0.32 |
| ▸ | CES2 | O00748 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.31 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.30 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2083897 | 1.00 | ACE (0.44) | ACEPOLBLMNACYP2C19HSD17B10 | |
| SCHEMBL19862758 | 1.00 | ACE (0.44) | ACEPOLBLMNACYP2C19HSD17B10 | |
| SCHEMBL29564420 | 0.89 | ACE (0.42) | ACEPOLBLMNACYP2C19HSD17B10 | |
| SCHEMBL26761920 | 0.83 | ACE (0.33) | ACEPOLBP2RX7 | |
| SCHEMBL12108512 | 0.83 | ACE (0.33) | ACEPOLBP2RX7 | |
| SCHEMBL18554231 | 0.81 | ACE (0.41) | ACEP2RX7KMT2AMEN1 | |
| SCHEMBL7451633 | 0.79 | KMT2A (0.37) | ACEPOLBLMNACYP2C19HSD17B10 | |
| SCHEMBL7451628 | 0.79 | KMT2A (0.37) | ACEPOLBLMNACYP2C19HSD17B10 | |
| SCHEMBL3856468 | 0.75 | ACE (0.38) | ACEPOLBHSD17B10 | |
| SCHEMBL21945623 | 0.74 | ACE (0.53) | ACEPOLBLMNACYP2C19HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11066396-B2 | 3-aryl- heteroaryl substituted 5-trifluoromethyl oxadiazoles as histonedeacetylase 6 (HDAC6) inhibitors | MERCK SHARP & DOHME CORP. (US) | 2021-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11066396-B2 | 3-aryl- heteroaryl substituted 5-trifluoromethyl oxadiazoles as histonedeacetylase 6 (HDAC6) inhibitors | HDAC6, HDAC1, HDAC5 | ACE 1230/4885POLB 2209/4885LMNA 4757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.